TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26430819

Group type: EXPERIMENTAL
Intervention: VR-enhanced CBT
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard Behavioral Program (SBP)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 163
Study: 24249842

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including group exercise training twice a week and daily walks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standardized information at discharge
Number of subjects: 18
Study: 22067197

Group type: EXPERIMENTAL
Intervention: Food intake (standard breakfast 30 to 10 minutes prior to dosing)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Positive control (400 mg of moxifloxacin)
Number of subjects: 55
Study: 21047410

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 5292
Study: 17650935

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN)
Number of subjects: 22
Study: 16105374

Group type: EXPERIMENTAL
Intervention: Enhanced occupational therapy support intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Practice-based intervention
Number of subjects: 12
Study: 11882227

Group type: EXPERIMENTAL
Intervention: Rocuronium pretreatment (1 min)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Rocuronium pretreatment (4 min)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study: 10902449

Group type: EXPERIMENTAL
Intervention: 5% prilocaine (1 mg/kg, n = 27)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 2% mepivacaine (0.8 mg/kg, n = 30)
Number of subjects: 57
Study: 9398880

Group type: EXPERIMENTAL
Intervention: LAC1 (1 week of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Number of subjects: 70

Group type: COMPARATOR
Intervention: LAC2 (2 weeks of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: LAC1
Number of subjects: 70

Group type: COMPARATOR
Intervention: LAC2
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: LAC1 and LAC2
Number of subjects: 70
Study: 1343606

Group type: EXPERIMENTAL
Intervention: Restricting episiotomy use in primiparous women
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Restricting episiotomy use in multiparous women
Number of subjects: 703

Group type: COMPARATOR
Intervention: Liberal or routine use of episiotomy
Number of subjects: 703

Group type: COMPARATOR
Intervention: Median episiotomy
Number of subjects: 703
Study: 3891188

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg twice a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg a day)
Number of subjects: 8
Study: 31055678

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Concentric training (CON)
Number of subjects: 17
Study: 28343051

Group type: EXPERIMENTAL
Intervention: Cariprazine 3–6 mg/d
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Cariprazine 9–12 mg/d
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study: 25256920

Group type: EXPERIMENTAL
Intervention: High Threat, Loss Frame, No Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: High Threat, Gain Frame, No Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Low Threat, Loss Frame, No Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Low Threat, Gain Frame, No Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: High Threat, Loss Frame, Yes Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: High Threat, Gain Frame, Yes Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Low Threat, Loss Frame, Yes Choice
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Low Threat, Gain Frame, Yes Choice
Number of subjects: 814
Study: 23436693

Group type: EXPERIMENTAL
Intervention: Partial body weight‐supported treadmill training (12 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional gait training (12 weeks)
Number of subjects: 10
Study: 22087222

Group type: EXPERIMENTAL
Intervention: Disci/Rhus toxicodendron compositum (verum)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 150

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 150
Study: 18992854

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,800 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 16856352

Group type: EXPERIMENTAL
Intervention: HRcon (constant heart rate)
Number of subjects: 7

Group type: COMPARATOR
Intervention: HRvar (variable heart rate)
Number of subjects: 7
Study: 12634023

Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health Jr. obesity prevention program
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1098
Study: 10848918

Group type: EXPERIMENTAL
Intervention: Recombinant celery profilin
Number of subjects: 17
Study: 9152674

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 3150

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 3150

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 3150

Group type: EXPERIMENTAL
Intervention: Propafenone (meta-analysis)
Number of subjects: 3150

Group type: EXPERIMENTAL
Intervention: Adverse cardiac events (general)
Number of subjects: 3150
Study: 8515191

Group type: EXPERIMENTAL
Intervention: Didactic teaching of the strategy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-instructional training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 90
Study: 3102585

Group type: COMPARATOR
Intervention: Verapamil SR, 360 mg
Number of subjects: 19
Study: 29432408

Group type: EXPERIMENTAL
Intervention: Zero-Profile (ZP) anterior cervical discectomy and fusion (ACDF)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Traditional ACDF with anterior cervical plate (ACP)
Number of subjects: 104
Study: 27863979

Group type: EXPERIMENTAL
Intervention: ADA fasting glucose concentration cutoff (5.6-6.9 mmol/L)
Number of subjects: 10844

Group type: EXPERIMENTAL
Intervention: ADA HbA1c cutoff (5.7-6.4%)
Number of subjects: 10844

Group type: EXPERIMENTAL
Intervention: IEC HbA1c cutoff (6.0-6.4%)
Number of subjects: 10844

Group type: EXPERIMENTAL
Intervention: WHO fasting glucose concentration cutoff (6.1-6.9 mmol/L)
Number of subjects: 10844

Group type: EXPERIMENTAL
Intervention: ADA HbA1c cutoff
Number of subjects: 10844

Group type: COMPARATOR
Intervention: ADA fasting glucose concentration clinical categories
Number of subjects: 10844

Group type: EXPERIMENTAL
Intervention: ADA HbA1c clinical categories
Number of subjects: 10844

Group type: COMPARATOR
Intervention: WHO fasting glucose concentration clinical categories
Number of subjects: 10844

Group type: COMPARATOR
Intervention: ADA and WHO 2 h glucose concentrations clinical categories
Number of subjects: 10844
Study: 26359119

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 662
Study: 23472309

Group type: EXPERIMENTAL
Intervention: Suction-above-the-cuff tracheotomy tubes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard tracheotomy tubes (Control)
Number of subjects: 18
Study: 21384219

Group type: EXPERIMENTAL
Intervention: Online care management through electronic messaging
Number of subjects: 208
Study: 18354933

Group type: EXPERIMENTAL
Intervention: Single dose of intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double dose of intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 17161044

Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis (PHF); administered within 6 hours of symptom onset by ambulance.
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis (PHF)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Inhospital treatment
Number of subjects: 1095
Study: 12679394

Group type: EXPERIMENTAL
Intervention: (123)I‐IMP‐ARG
Number of subjects: 39

Group type: COMPARATOR
Intervention: H(2)(15)O PET
Number of subjects: 39
Study: 10735799

Group type: EXPERIMENTAL
Intervention: 7.5 microg sufentanil
Number of subjects: 42

Group type: COMPARATOR
Intervention: 40 microg fentanyl
Number of subjects: 42
Study: 9190053

Group type: EXPERIMENTAL
Intervention: Nonthreatening success condition
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Threatening failure condition
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 96
Study: 8999692

Group type: EXPERIMENTAL
Intervention: Holter EKG monitoring during gastroscopic examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Holter EKG monitoring)
Number of subjects: 0
Study: 2724276

Group type: EXPERIMENTAL
Intervention: Safflower oil (linoleic acid supplementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraffin oil (placebo)
Number of subjects: 0
Study: 31619274

Group type: EXPERIMENTAL
Intervention: Direct lateral nasal pressure applied intraoperatively for 5 minutes after lateral osteotomies
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Direct lateral nasal pressure applied intraoperatively
Number of subjects: 16
Study: 28626589

Group type: EXPERIMENTAL
Intervention: Exercise (Ex) and lunch labelled as low in fat (LF)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise (Ex) and lunch labelled as high in fat (HF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rest and lunch labelled as low in fat (LF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rest and lunch labelled as high in fat (HF)
Number of subjects: 14
Study: 26190132

Group type: EXPERIMENTAL
Intervention: Medication review by an experienced hospital pharmacist within the ED
Number of subjects: 0
Study: 23827009

Group type: EXPERIMENTAL
Intervention: Coping Cat (experimental group)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No program (control group)
Number of subjects: 130
Study: 22573261

Group type: EXPERIMENTAL
Intervention: Lightweight (LW) mesh
Number of subjects: 392

Group type: COMPARATOR
Intervention: Heavyweight (HW) mesh
Number of subjects: 392
Study: 20003464

Group type: EXPERIMENTAL
Intervention: S. sonnei
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S. flexneri
Number of subjects: 0
Study: 17395895

Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO), 7.5 mg, single dose
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 52
Study: 15310354

Group type: EXPERIMENTAL
Intervention: Left lateral position (LL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supine, wedged position (SW)
Number of subjects: 100
Study: 11730399

Group type: EXPERIMENTAL
Intervention: Small trials with inadequate allocation sequence generation
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Small trials with inadequate allocation concealment
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Small trials with no double blinding
Number of subjects: 190

Group type: COMPARATOR
Intervention: Large trials with adequate generation of the allocation sequence
Number of subjects: 190

Group type: COMPARATOR
Intervention: Large trials with adequate allocation concealment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Large trials with adequate double blinding
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Reported follow-up
Number of subjects: 190
Study: 9743306

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in four weekly doses
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in every‐4‐week dose
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2))
Number of subjects: 173
Study: 9815951

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day
Number of subjects: 13
Study: 2299605

Group type: EXPERIMENTAL
Intervention: Daily intravesical injections of 250 mg of prostaglandin F2 alpha (PGF2 alpha) (n = 23)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Daily 10‐mg PGE2 vaginal suppository (n = 22)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Daily saline injection to the bladder (control group, n = 24)
Number of subjects: 69
Study: 7441695

Group type: EXPERIMENTAL
Intervention: Instruction from professional patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Instruction from gynecologist with a clinic patient (Control)
Number of subjects: 40
Study: 29388856

Group type: EXPERIMENTAL
Intervention: Atropine (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 120
Study: 26714731

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 25649801

Group type: EXPERIMENTAL
Intervention: High-dose B vitamin therapy
Number of subjects: 3680

Group type: COMPARATOR
Intervention: Low-dose B vitamin therapy
Number of subjects: 3680
Study: 24199747

Group type: EXPERIMENTAL
Intervention: Exercise prescription and devices for monitoring of risk factors with a smartphone data portal equipped with a mobile health application
Number of subjects: 149

Group type: COMPARATOR
Intervention: Exercise prescription
Number of subjects: 149
Study: 21393611

Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n = 14)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus plus enalapril and atorvastatin (SRL group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Enalapril plus atorvastatin (CONTROL group, n = 9)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Enalapril plus atorvastatin (CONTROL group)
Number of subjects: 23
Study: 19590473

Group type: EXPERIMENTAL
Intervention: 1% lignocaine injections
Number of subjects: 34

Group type: COMPARATOR
Intervention: N-saline injections
Number of subjects: 34
Study: 16836814

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Etch and Prime 3.0) with Degufill Mineral RBC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional two-bottle adhesive system (Gluma Solid Bond) with Wet Bond technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional two-bottle adhesive system (Gluma Solid Bond) with Dry Bond technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional two-bottle adhesive system (Gluma Solid Bond) with Wet Bond vs Dry Bond
Number of subjects: 15
Study: 14689341

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 686

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 686
Study: 10868865

Group type: EXPERIMENTAL
Intervention: Troglitazone monotherapy (600 mg daily)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Troglitazone with sulfonylurea (600 mg daily)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Troglitazone with insulin (600 mg daily)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Troglitazone (all combinations, 600 mg daily)
Number of subjects: 758
Study: 1839798

Group type: EXPERIMENTAL
Intervention: 17‐beta estradiol valerianate (E2) (2 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Micronized E2 (2 mg) plus estriol (E3) (1 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: E2 + E3
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CPA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low calorie diet
Number of subjects: 44
Study: 6222901

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg twice a day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 36
Study: 30314739

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention program
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 127
Study: 29138224

Group type: EXPERIMENTAL
Intervention: Exercise + Metformin (E + M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 0
Study: 26325273

Group type: EXPERIMENTAL
Intervention: Titanium-sapphire laser trabeculoplasty (TLT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard Q-Switched Nd:YAG laser trabeculoplasty (SLT)
Number of subjects: 37
Study: 25304007

Group type: EXPERIMENTAL
Intervention: CT/TT genotypes of XRCC2 C41657T
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: XRCC2 protein expression in CRC patients with CT/TT genotypes
Number of subjects: 508

Group type: COMPARATOR
Intervention: G4234C polymorphisms of XRCC2
Number of subjects: 508
Study: 22067089

Group type: EXPERIMENTAL
Intervention: Intensified Medical therapy
Number of subjects: 622

Group type: COMPARATOR
Intervention: Standard Medical therapy
Number of subjects: 622

Group type: COMPARATOR
Intervention: Resuscitation orders
Number of subjects: 622
Study: 20861211

Group type: EXPERIMENTAL
Intervention: Coffee mannooligosaccharides (MOS) beverage (4 g/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 54
Study: 18227044

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alanyl-glutamine (Gln) with standard total parenteral nutrition (TPN) for 1 week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (control) with standard total parenteral nutrition (TPN) for 1 week
Number of subjects: 50
Study: 15943942

Group type: EXPERIMENTAL
Intervention: Timeline Follow-Back Instrument (TLFB)
Number of subjects: 0
Study: 12297407

Group type: EXPERIMENTAL
Intervention: therapeutic vaccination with pre‐S1, pre‐S2 and S antigenic components of HBV
Number of subjects: 22
Study: 10626187

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) levels in anti-HCV positive patients with HCC
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (anti-HCV positive patients without HCC)
Number of subjects: 336
Study: 8560112

Group type: EXPERIMENTAL
Intervention: Intravenous Diltiazem (DTZ)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intravenous Nitroglycerin (NTG)
Number of subjects: 43
Study: 2075139

Group type: EXPERIMENTAL
Intervention: Cimetidine plus pirenzepine (50 mg before bedtime)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sucralfate (4.0 g daily)
Number of subjects: 70
Study: 6828827

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme including physical exercise, counselling of patients and relatives, and social measures over a 3-month period
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no rehabilitation programme)
Number of subjects: 171
Study: 31748259

Group type: EXPERIMENTAL
Intervention: High genetically predicted plasma homocysteine levels (PHL)
Number of subjects: 7004

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for women
Number of subjects: 7004

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 7004

Group type: EXPERIMENTAL
Intervention: MR-Egger and weighted median regression
Number of subjects: 7004
Study: 29395715

Group type: EXPERIMENTAL
Intervention: Long-length clear corneal incisions (≥1.75 mm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Short-length clear corneal incisions (<1.75 mm)
Number of subjects: 120
Study: 26371143

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 518

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 518
Study: 25344019

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: CNP risk factors
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Haematoma risk factors
Number of subjects: 821
Study: 24132044

Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention
Number of subjects: 199
Study: 20571386

Group type: EXPERIMENTAL
Intervention: Azathioprine/6-mercaptopurine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroimidazole antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation and ileocolonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative immunomodulators and antitumor necrosis factor agents
Number of subjects: 0
Study: 18615321

Group type: EXPERIMENTAL
Intervention: Outreach Treatment Program (OTP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard Addiction Care Services (Control)
Number of subjects: 124
Study: 16041475

Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Number of subjects: 33
Study: 12825037

Group type: EXPERIMENTAL
Intervention: TCRFTA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham-placebo
Number of subjects: 90
Study: 10491351

Group type: EXPERIMENTAL
Intervention: Phenylephrine test
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Spectral analysis (alpha(c) index)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Controlled breathing
Number of subjects: 49
Study: 8677455

Group type: EXPERIMENTAL
Intervention: Dose level 1 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose level 2 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose level 3 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12
Study: 1990895

Group type: EXPERIMENTAL
Intervention: Propofol (1-3 mg.kg-1 injected over 10-30 s)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol (1-3 mg.kg-1 injected over 10-30 s) with halothane (1-3%)
Number of subjects: 90
Study: 6760217

Group type: EXPERIMENTAL
Intervention: Diclofensine (mean daily dose of 57.5 mg for 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diclofensine
Number of subjects: 40
Study: 30991863

Group type: EXPERIMENTAL
Intervention: Apatinib mesylate combined with chemotherapy (taxane, irinotecan, and fluorouracil)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (chemotherapy only: taxane, irinotecan, and fluorouracil)
Number of subjects: 119